Results for mTOR Pathway

1 - 9 of 9

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.

E-mail:

grupp [at] chop.edu

Elizabeth J.K. Bhoj, MD PhD

Dr. Bhoj's genetics research aims to discover new human disease genes, their mechanisms, and potential targeted therapies. In addition to ongoing gene discovery efforts, Dr. Bhoj focuses on three novel genes that lead to pediatric neurologic dysfunction: TBC1 domain-containing kinase, Histone 3.3 (H3F3A and H3F3B), and MAP4K4.

E-mail:

bhoje [at] chop.edu

Making Meaningful Connections: Q&A With Diversity Fellow Marisa Jefferies

Published on

Nov 28, 2022

in Cornerstone Blog

Q&A With Diversity Fellow Marisa Jefferies

Featured Diversity Fellow Marisa Jeffries, PhD, is excited to study how HIV-1 infection may affect white matter development during adolescence.

Novel Gene Mutation Found in Lymphatic Disorder

Published on

Aug 28, 2018

in Press Releases

CHOP Researchers Report Potential Treatment that Restores Normal Anatomy in Animal Models

Biomarkers, Clues to Possible Therapy Found in Novel Childhood Neurogenetic Disease

Published on

Feb 22, 2018

in Press Releases

CHOP Study of TBCK Mutation Sheds Light on Biology of Neurodegeneration

Biology of Childhood Brain Tumor Subtypes Offers Clues to Precision Treatments

Published on

Oct 16, 2017

in Press Releases

CHOP Researchers Reveal Differences among Gene Fusions in Low-Grade Pediatric Brain Tumors

In The News: New Syndrome Named, National Honor for Pediatric Oncologist

Published on

Apr 8, 2016

in Cornerstone Blog

Check out the most exciting research news from The Children’s Hospital of Philadelphia this week. From leading a group of international researchers who identified a new syndrome to working on a prestigious panel that will give guidance about ways to advance treatments for children with cancer, CHOP researchers are putting pediatric research in motion.

Teachey Laboratory

The Teachey Lab studies perturbations in leukemic cell signal transduction pathways with the aim of identifying targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome.

Bhoj Lab Research

Thousands of children are suspected to have a genetic disorder but have no diagnosis, even after expert evaluation. Many of these children have yet-undiscovered genetic syndromes, and the Bhoj Lab aims to provide answers to families about their child's medical issues and work toward targeted therapies for genetic disorders. The lab uses advanced sequencing technology to identify these novel syndromes. Two of the syndromes focused on in the lab are caused by disruption of Histone 3.3 (H3F3A and H3F3B) and TBC1 domain-containing Kinase (TBCK).